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Li et al. (2006) have shown that TOR complex 1 in yeast binds directly to the rDNA promoter and thereby activates Pol I-de-
pendent synthesis of 35S RNA. This is an important advance in the understanding of how ribosome biogenesis is regulated
in response to environmental conditions.The regulation of ribosome biogenesis is
a key aspect of cell growth control. In
a robustly growing cell, ribosome bio-
genesis is a major consumer of cellular
energy and building blocks. Thus, as
growth conditions change, cells must
accurately and rapidly rebalance ribo-
some production with the availability of
resources. The regulation of ribosome
biogenesis occurs primarily at the tran-
scriptional level and involves all three
nuclear RNA polymerases (Pol I thru III)
(see Figure 1). Pol I transcribes rDNA
encoding the 35S rRNA precursor, Pol
II (Pol II) transcribes the ribosomal pro-
tein (RP) genes, and Pol III produces
5S rRNA (and tRNA). It has been esti-
mated that the transcription of these
genes encoding structural components
of the ribosome accounts for up to
90% of total cellular transcription in
a rapidly growing cell (Warner et al.,
2001). The growth conditions that im-
pinge on ribosome biogenesis include
nutrients and stress.
A central regulator of cell growth and
metabolism in all eukaryotes is the Ser/
Thr kinase TOR (target of rapamycin) and
its namesake signaling network (for re-
view see Wullschleger et al., 2006). TOR
controls cell growth in response to nutri-
ents and stress and exists in two struc-
turally and functionally distinct protein
complexes termed TORC1 (TOR com-
plex 1) and TORC2. In yeast, TORC1
contains either one of the two TORs
TOR1 and TOR2, whereas TORC2 con-
tains TOR2 but not TOR1. The two
TORCs control different sets of growth-
related processes. TORC1, but not
TORC2, controls translation and ribo-
some biogenesis. Only TORC1 is in-
hibited by rapamycin, an immunosup-
pressive and anticancer drug. In yeast,
inactivation of TORC1 by rapamycin
treatment (or nutrient deprivation) leads
to a fast and strong downregulation of
essentially all genes involved in ribosome
biogenesis (see Figure 1). This downreg-CELL METABOLISM : OCTOBER 2006ulation is due to a general inhibition of
Pol I and Pol III activities and reduced
Pol II activity at RP gene promoters
(Powers and Walter, 1999). Rapamycin
treatment also leads to a strong repres-
sion of Pol II genes encoding nonriboso-
mal proteins involved in ribosomesynthe-
sis and maturation, collectively termed
the Ribi (ribosome biogenesis) regulon
(Jorgensen et al., 2004). The Ribi regulon
is the largest set of coordinately ex-
pressed genes in yeast, again illustrating
the magnitude of ribosome biogenesis
and its regulation by TOR. How all three
RNA polymerases are regulated by the
TORC1 signaling pathway is largely un-
known. In general, TORC1 controls gene
expression by regulating the subcellular
localization of a variety of specific tran-
scription factors. For example, cytoplas-
mic TORC1 controls nuclear localization
of the two transcription factors SFP1
and CRF1 that act at Pol II-dependent
RP gene promoters (Jorgensen et al.,
2004; Martin and Hall, 2005).
Zheng and coworkers (Li et al., 2006)
have now presented evidence that
TORC1 in yeast controls Pol I more inti-
mately than previously anticipated. This
study shows that a significant fraction
of TOR1 (i.e., TORC1) is localized to the
nucleus and binds directly to the 35S
rDNA promoter. Upon rapamycin treat-
ment (inhibition of TOR1 activity), TOR1
is exported from the nucleus by the ex-
portin CRM1 and a newly characterized
NES (nuclear export signal) in TOR1.
Upon favorable growth conditions
(TOR1 is active), TOR1 is imported into
the nucleus by the importin SRP1 and
an also newly characterized NLS (nuclear
localization signal) near the kinase do-
main in TOR1. Furthermore, using a ge-
netic trick to create ‘‘conditional’’ muta-
tions in the NES and NLS, they show
that nuclear import of TOR1 is necessary
for 35S rRNA synthesis but of no conse-
quence for expression of TOR1-regu-
lated Pol II target genes. TOR1 bindsdirectly to the 35S rDNA promoter via
an also heretofore uncharacterized HTH
(helix turn helix) motif. Deletion of the
HTH motif specifically affects 35S
rRNA synthesis by Pol I but not the ex-
pression of known TOR1-regulated Pol
II genes. Thus, TOR1 appears to acti-
vate Pol I directly at the promoter
whereas, as shown previously, it acti-
vates Pol II indirectly from the cyto-
plasm. Interestingly, TORC1 can still
perform its cytoplasmic function when
stuck in the nucleus due to an NES mu-
tation in TOR1.
A remaining important issue is whether
TOR1 kinase activity, which is necessary
for TOR1 nuclear import, is also required
to activate Pol I at the rDNA promoter.
The findings presented by Zheng and co-
workers raise the possibility that TORC1
directly phosphorylates one of the Pol I
subunits or its associated transcription
factors. One such candidate factor could
be RRN3 (TIF1-A in human cells), a key
activator of Pol I in yeast and mammalian
cells (for a review see Moss, 2004). In
growing yeast cells, RRN3 associates
with the RPA43 subunit of Pol I in a
TORC1-dependent manner and thereby
activates Pol I. The histone deacetylase
RPD3 has also been proposed to act at
rDNA promoters in a TORC1-sensitive
manner, although there is disagreement
on this finding. Nuclear TORC1 may
have several targets involved in rDNA
transcription, maintenance of nucleolar
structure, and nuclear import/export.
The elucidation of these potentially direct
nuclear substrates and the exact mecha-
nisms of transcriptional regulation will
significantly enhance the understanding
of cell growth control.
The observations of Li et al. (2006)
provide new insights into the role of
TORC1 in ribosome biogenesis but are
also quite surprising. One intriguing find-
ing of this report is the nuclear localiza-
tion of TOR1. This is in apparent contrast
to previous reports that showed by259
P R E V I E W Sseveral techniques, including subcellular
fractionation, indirect immunofluores-
cence (IF), and immunoelectron micros-
copy (IEM), that TOR in yeast is associ-
ated with internal membranes, mainly
at or near the plasma membrane (Kunz
et al., 2000; Wedaman et al., 2003). Sev-
eral other yeast TORC1 components
have also been localized to discrete in-
tracellular locations but not within the
nucleus (e.g., Wedaman et al., 2003).
Moreover, the localization pattern of
TOR1 and TOR2 was reported previ-
ously to be insensitive to rapamycin
treatment. Thus, additional studies are
necessary to substantiate the functional
significance of TOR1’s nuclear localiza-
tion. For example, it will be important
to determine whether the same holds
true for TOR2, which can functionally
replace TOR1 within TORC1. However,
in line with Li et al. (2006), signaling
Figure 1. Transcriptional control of ribosome bio-
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260kinases are often found bound to genes
(Pokholok et al., 2006), and mTOR in
mammalian cells has been shown to
shuttle in and out of the nucleus and
this shuttling is important for mTOR sig-
naling (Bachmann et al., 2006). It will be
of interest to determine whether mTOR
binds directly to promoters in mamma-
lian cells.
TOR coordinates the relative activity
of all three RNA polymerases to achieve
the proper stoichiometry of ribosomal
components. Do Li et al. (2006) provide
insight into this aspect of TOR-medi-
ated regulation of ribosome biogene-
sis? A recent report by Laferte et al.
(2006) suggests that rRNA synthesis
by Pol I is a key determinant for tran-
scriptional regulation of all ribosomal
components, including ribosomal pro-
teins and 5S rRNA. Laferte et al.
(2006) constructed a functional, rapa-
mycin-insensitive RNA Pol I by fusing
the Pol I-specific transcription factor
RRN3 to the Pol I subunit RPA43. This
RRN3-Pol I hybrid functioned normally
under good growth conditions. How-
ever, when cells harboring RRN3-Pol I
were treated with rapamycin, or starved
for glucose, 35S rRNA synthesis re-
mained at an elevated level. Surpris-
ingly, these cells also failed to properly
attenuate expression of Pol II-depen-
dent RP genes and Pol III-dependent
5S rRNA synthesis. These results sug-
gest the appealing possibility that TOR
may coordinate the three RNA poly-
merases via Pol I. However, Li et al.
(2006) observed that mutations that al-
ter TOR1-mediated regulation of Pol I
have no effect on expression of RP
genes. Thus, the mechanism of coordi-
nated control of ribosomal components
by TOR remains to be elucidated.s antagonism
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